CarMax Inc.'s stock (KMX) experienced a 6.5% decline in premarket trade on Thursday following the release of its second-quarter earnings report. The Richmond, Va.-based used car retailer faced continued pressure within the sector, resulting in a decrease in net income compared to the same period last year. For the quarter ending on August 31, CarMax reported a net income of … [Read more...] about CarMax Reports Decline in Q2 Earnings
Apple Shares Struggle as iPhone 15 Fails to Boost Stock
Apple's shares, represented by the ticker symbol AAPL, have been experiencing a downturn, making it the worst month for the technology giant so far in 2023. Surprisingly, even the introduction of the highly anticipated iPhone 15 hasn't managed to reverse the trend. In premarket trading on Thursday, Apple shares saw a marginal increase of 0.3% and were priced at $169.99. … [Read more...] about Apple Shares Struggle as iPhone 15 Fails to Boost Stock
Apple Shares Head for Worst Month of 2023
Apple shares are on track for their worst month of 2023, despite the recent launch of the highly anticipated iPhone 15. The stock has been struggling, with no relief in sight. Current Status of Apple Shares In premarket trading on Thursday, Apple (ticker: AAPL) shares were slightly up by 0.3% at $169.99. However, the stock closed at its lowest level since early May the previous … [Read more...] about Apple Shares Head for Worst Month of 2023
Disinflation Trend Persists, New Measures of Inflation Show
The latest gross domestic product report, released on Thursday, highlighted two new measures of inflation that support the continuation of the disinflation trend. The Commerce Department, in response to user requests, broke down the price indexes for Personal Consumption Expenditures (PCE) excluding food, energy, and housing, as well as PCE services excluding energy and … [Read more...] about Disinflation Trend Persists, New Measures of Inflation Show
Bionomics Reports Successful Study of Lead Drug Candidate in PTSD
Shares of biotechnology company Bionomics experienced a significant surge in early trading on Thursday following the announcement of successful results from their Phase 2b study of their lead drug candidate for post-traumatic stress disorder (PTSD). Promising Results and Market Reaction The Australia-based company's shares soared almost four-fold to $3.89 as investors reacted … [Read more...] about Bionomics Reports Successful Study of Lead Drug Candidate in PTSD
